Casein kinase 1 functions as both penultimate and ultimate kinase in regulating Cdc25A destruction

Oncogene

Volumn 29, Issue 23, 2010, Pages 3324-3334

  Honaker, Y ^a   Piwnica Worms, H ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

TrCP; Cell cycle; Chk1; Ubiquitin

Indexed keywords

CASEIN KINASE IALPHA; CDC25A ENZYME; PHOSPHATASE; UBIQUITIN; UNCLASSIFIED DRUG;

ARTICLE; CONTROLLED STUDY; GENOTOXICITY; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN DEGRADATION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION;

BETA-TRANSDUCIN REPEAT-CONTAINING PROTEINS; CASEIN KINASE IALPHA; CDC25 PHOSPHATASES; DNA DAMAGE; HELA CELLS; HUMANS; LUCIFERASES, FIREFLY; PHOSPHORYLATION; UBIQUITIN;

EID: 77953479905     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2010.96     Document Type: Article

References (38)

1. Abramoff MD, Magelhaes PJ, Ram SJ. (2004). Image processing with Image J. Biophotonics Int 11: 36-42.
2. Bain J, Plater L, Elliott M, Shpiro N, Hastie CJ, McLauchlan H et al. (2007). The selectivity of protein kinase inhibitors: a further update. Biochem J 408: 297-315.
3. Bartek J, Lukas J. (2001). Pathways governing G1/S transition and their response to DNA damage. FEBS Lett 490: 117-122.
4. Behrend L, Milne DM, Stoter M, Deppert W, Campbell LE, Meek DW et al. (2000). IC261, a specific inhibitor of the protein kinases casein kinase 1-delta and-epsilon, triggers the mitotic checkpoint and induces p53-dependent postmitotic effects. Oncogene 19: 5303-5313.
5. Bernardi R, Lieberman DA, Hoffman B. (2000). Cdc25A stability is controlled by the ubiquitin-proteasome pathway during cell cycle progression and terminal differentiation. Oncogene 19: 2447-2454.
6. Blomberg I, Hoffman I. (1999). Ectopic expression of Cdc25A accelerates the G1/S transition and leads to premature activation of cyclin E-and cyclin A-dependent kinases. Mol Cell Biol 19: 6183-6194.
7. Boutros R, Dozier C, Ducommun B. (2006). The when and wheres of CDC25 phosphatases. Curr Opin Cell Biol 18: 185-191.
8. Busino L, Chiesa M, Draetta GF, Donzelli M. (2004). Cdc25A phosphatase: combinatorial phosphorylation, ubiquitylation and proteolysis. Oncogene 23: 2050-2056.
9. Busino L, Donzelli M, Chiesa M, Guardavaccaro D, Ganoth D, Dorrello NV et al. (2003). Degradation of Cdc25A by beta-TrCP during S phase and in response to DNA damage. Nature 426: 87-91.
10. Chen L, Li C, Pan Y, Chen J. (2005). Regulation of p53-MDMX interaction by casein kinase 1 alpha. Mol Cell Biol 25: 6509-6520.
11. Chen M-S, Ryan CE, Piwnica-Worms H. (2003). Chk1 kinase negatively regulates mitotic function of Cdc25A phosphatase through 14-3-3 binding. Mol Cell Biol 23: 7488-7497.
12. Cohen P, Frame S. (2001). The renaissance of GSK3. Nat Rev Mol Cell Biol 2: 769-776.
13. Doble BW, Woodgett JR. (2003). GSK-3: tricks of the trade for a multi-tasking kinase. J Cell Sci 116: 1175-1186.
14. Donzelli M, Busino L, Chiesa M, Ganoth D, Hershko A, Draetta GF. (2004). Hierarchical order of phosphorylation events commits Cdc25A to betaTrCP-dependent degradation. Cell Cycle 3: 469-471.
15. Donzelli M, Squatrito M, Ganoth D, Hershko A, Pagano M, Draetta GF. (2002). Dual mode of degradation of Cdc25 A phosphatase. EMBO J 21: 4875-4884.
16. Falck J, Mailand N, Syljuasen RG, Bartek J, Lukas J. (2001). The ATM-Chk2-Cdc25A checkpoint pathway guards against radio-resistant DNA synthesis. Nature 410: 842-847.
17. Flotow H, Graves PR, Wang AQ, Fiol CJ, Roeske RW, Roach PJ. (1990). Phosphate groups as substrate determinants for casein kinase I action. J Biol Chem 265: 14264-14269.
18. Galaktionov K, Chen X, Beach D. (1996). Cdc25 cell-cycle phos-phatase as a target of c-myc. Nature 382: 511-517.
19. Goloudina A, Yamaguchi H, Chervyakova DB, Appella E, Fornace Jr AJ, Bulavin DV. (2003). Regulation of human Cdc25A stability by serine 75 phosphorylation is not sufficient to activate a S-phase checkpoint. Cell Cycle 2: 473-478.
20. Gross SD, Anderson RA. (1998). Casein kinase I: spatial organization and positioning of a multifunctional protein kinase family. Cell Signal 10: 699-711.
21. Hassepass I, Voit R, Hoffmann I. (2003). Phosphorylation at serine-75 is required for UV-mediated degradation of human Cdc25A phosphatase at the S-phase checkpoint. J Biol Chem 278: 29824-29829.
22. Jin J, Shirogane T, Xu L, Nalepa G, Qin J, Elledge SJ et al. (2003). SCFbeta-TRCP links Chk1 signaling to degradation of the Cdc25A protein phosphatase. Genes Dev 17: 3062-3074.
23. Kanemori Y, Uto K, Sagata N. (2005). Beta-TrCP recognizes a previously undescribed nonphosphorylated destruction motif in Cdc25A and Cdc25B phosphatases. Proc Natl Acad Sci USA 102: 6279-6284.
24. Kang T, Wei Y, Honaker Y, Yamaguchi H, Appella E, Hung MC et al. (2008). GSK-3beta targets Cdc25A for ubiquitin-mediated proteolysis, and GSK-3beta inactivation correlates with Cdc25A overproduction in human cancers. Cancer Cell 13: 36-47.
25. Knippschild U, Gocht A, Wolff S, Huber N, Lohler J, Stoter M. (2005). The casein kinase 1 family: participation in multiple cellular processes in eukaryotes. Cell Signal 17: 675-689.
26. Kristjansdottir K, Rudolph J. (2004). Cdc25 phosphatases and cancer. Chem Biol 11: 1043-1051.
27. Loffler H, Syljuasen RG, Bartkova J, Worm J, Lukas J, Bartek J. (2003). Distinct modes of deregulation of the proto-oncogenic Cdc25A phosphatase in human breast cancer cell lines. Oncogene 22: 8063-8071.
28. Mailand N, Falck J, Lukas C, Syljuasen RG, Welcker M, Bartek J et al. (2000). Rapid destruction of human Cdc25A in response to DNA damage. Science 288: 1425-1429.
29. Melixetian M, Klein DK, Sorensen CS, Helin K. (2009). NEK11 regulates CDC25A degradation and the IR-induced G2/M checkpoint. Nat Cell Biol 11: 1247-1253.
30. Molinari M, Mercurio C, Dominguez J, Goubin F, Draetta GF. (2000). Human Cdc25A inactivation in response to S phase inhibition and its role in preventing premature mitosis. EMBO Rep 1: 71-79.
31. Nash P, Tang X, Orlicky S, Chen Q, Gertler FB, Mendenhall MD et al. (2001). Multisite phosphorylation of a CDK inhibitor sets a threshold for the onset of DNA replication. Nature 414: 514-521.
32. Ray D, Kiyokawa H. (2008). CDC25A phosphatase: a rate-limiting oncogene that determines genomic stability. Cancer Res 68: 1251-1253.
33. Ray D, Terao Y, Nimbalkar D, Chu LH, Donzelli M, Tsutsui T et al. (2005). Transforming growth factor beta facilitates beta-TrCP-mediated degradation of Cdc25A in a Smad3-dependent manner. Mol Cell Biol 25: 3338-3347.
34. Rena G, Bain J, Elliott M, Cohen P. (2004). D4476, a cell-permeant inhibitor of CK1, suppresses the site-specific phosphorylation and nuclear exclusion of FOXO1a. EMBO Rep 5: 60-65.
35. Vigo E, Muller H, Properini E, Hatevoer G, Cartwright P, Moroni MC et al. (1999). CDC25A phosphatase is a target of E2F and is required for efficient E2F-induced S phase. Mol Cell Biol 19: 6379-6395.
36. Zabludoff SD, Deng C, Grondine MR, Sheehy AM, Ashwell S, Caleb BL et al. (2008). AZD7762, a novel checkpoint kinase inhibitor, drives checkpoint abrogation and potentiates DNA-targeted therapies. Mol Cancer Ther 7: 2955-2966.
37. Zhao H, Watkins JL, Piwnica-Worms H. (2002). Disruption of the checkpoint kinase 1/cell division cycle 25A pathway abrogates ionizing radiation-induced S and G2 checkpoints. Proc NatlAcad Sci USA 99: 14795-14800.
38. Zhou BP, Deng J, Xia W, Xu J, Li YM, Gunduz M et al. (2004). Dual regulation of Snail by GSK-3beta-mediated phosphorylation in control of epithelial-mesenchymal transition. Nat Cell Biol 6: 931-940.